CTSO Cytosorbents Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTSO

Price (delayed)

$0.809

Market cap

$43.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$46.25M

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the ...

Highlights
The gross profit rose by 8% year-on-year
Cytosorbents's revenue has increased by 4.8% YoY
The quick ratio has shrunk by 51% YoY but it is up by 10% QoQ
The equity has declined by 34% year-on-year but it is up by 26% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.cytosorbents.com
Peers: BSX NEPH HOLX

Key stats

What are the main financial stats of CTSO
Market
Shares outstanding
54.29M
Market cap
$43.92M
Enterprise value
$46.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.54
Price to sales (P/S)
0.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.27
Earnings
Revenue
$36.35M
EBIT
-$29.16M
EBITDA
-$27.14M
Free cash flow
-$22.19M
Per share
EPS
-$0.64
Free cash flow per share
-$0.5
Book value per share
$0.52
Revenue per share
$0.81
TBVPS
$1.19
Balance sheet
Total assets
$53.26M
Total liabilities
$29.99M
Debt
$17.94M
Equity
$23.28M
Working capital
$11.16M
Liquidity
Debt to equity
0.77
Current ratio
1.77
Quick ratio
1.49
Net debt/EBITDA
-0.09
Margins
EBITDA margin
-74.7%
Gross margin
61.6%
Net margin
-78.4%
Operating margin
-85.9%
Efficiency
Return on assets
-54.1%
Return on equity
-120.2%
Return on invested capital
-67%
Return on capital employed
-75.3%
Return on sales
-80.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
-1.34%
1 week
1.13%
1 month
-10.83%
1 year
-70.04%
YTD
-27.12%
QTD
-14.84%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$36.35M
Gross profit
$22.39M
Operating income
-$31.21M
Net income
-$28.51M
Gross margin
61.6%
Net margin
-78.4%
The net margin has declined by 24% since the previous quarter but it has increased by 17% year-on-year
CTSO's net income is down by 22% since the previous quarter but it is up by 13% year-on-year
Cytosorbents's operating margin has decreased by 13% QoQ but it has increased by 6% YoY
CTSO's operating income is down by 11% since the previous quarter

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
1.54
P/S
0.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.27
CTSO's EPS is down by 21% from the previous quarter but it is up by 15% YoY
CTSO's P/B is 81% lower than its 5-year quarterly average of 8.3 and 66% lower than its last 4 quarters average of 4.6
The equity has declined by 34% year-on-year but it is up by 26% since the previous quarter
The stock's price to sales (P/S) is 82% less than its 5-year quarterly average of 5.7 and 66% less than its last 4 quarters average of 3.0
Cytosorbents's revenue has increased by 4.8% YoY

Efficiency

How efficient is Cytosorbents business performance
The ROE has plunged by 63% YoY and by 37% from the previous quarter
The ROA has decreased by 27% QoQ and by 15% YoY
The ROIC has contracted by 24% from the previous quarter but it has grown by 17% YoY
CTSO's ROS is down by 22% from the previous quarter but it is up by 18% YoY

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The company's total assets is 78% higher than its total liabilities
The quick ratio has shrunk by 51% YoY but it is up by 10% QoQ
CTSO's current ratio is down by 49% year-on-year but it is up by 10% since the previous quarter
The debt is 23% smaller than the equity
The debt to equity has soared by 51% year-on-year but it is down by 21% since the previous quarter
The equity has declined by 34% year-on-year but it is up by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.